Medexus Pharmaceuticals Inc.
MDP.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -9.78% | -4.65% | 18.96% | -13.27% | -13.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -9.78% | -4.65% | 18.96% | -13.27% | -13.54% |
| Cost of Revenue | -23.54% | -11.58% | 17.73% | -15.79% | -14.17% |
| Gross Profit | -0.35% | 0.66% | 19.94% | -11.46% | -13.10% |
| SG&A Expenses | 17.56% | 17.43% | 2.61% | -18.66% | -13.03% |
| Depreciation & Amortization | 72.06% | 68.12% | 21.27% | 7.72% | -2.49% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.54% | 8.24% | 10.86% | -17.07% | -14.08% |
| Operating Income | -80.37% | -110.27% | 141.14% | 15.36% | -10.54% |
| Income Before Tax | -67.63% | -176.67% | 210.69% | 40.29% | 114.93% |
| Income Tax Expenses | 273.68% | -190.35% | 156.32% | -675.83% | -124.46% |
| Earnings from Continuing Operations | -73.63% | -172.57% | 237.27% | 110.06% | 200.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -73.63% | -172.57% | 237.27% | 110.06% | 200.61% |
| EBIT | -80.37% | -110.27% | 141.14% | 15.36% | -10.54% |
| EBITDA | -42.93% | -49.01% | 83.59% | 13.14% | -8.69% |
| EPS Basic | -80.00% | -159.94% | 234.39% | 108.41% | 148.45% |
| Normalized Basic EPS | -99.13% | -96.72% | 208.78% | 260.74% | 110.99% |
| EPS Diluted | -80.00% | -159.94% | 234.39% | 108.41% | 166.67% |
| Normalized Diluted EPS | -99.13% | -96.72% | 208.78% | 260.74% | 110.99% |
| Average Basic Shares Outstanding | 31.89% | 21.08% | 2.04% | 20.14% | 20.90% |
| Average Diluted Shares Outstanding | 31.89% | 21.08% | 2.04% | 20.14% | 20.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |